Astria Therapeutics to Speak at Eastern Allergy Conference

Astria Therapeutics, Inc., a biopharmaceutical company listed on NASDAQ under the ticker ATXS, has announced that it will present the final data from its Phase 1a study of STAR-0215 at the upcoming Eastern Allergy Conference. This event is scheduled to take place in Palm Beach, Florida, on June 1, 2024.

Jessica Best, who serves as the Vice President of Medical Affairs at Astria Therapeutics, will be presenting a poster titled "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema." The presentation is set for 9:45 AM EST on Saturday, June 1.

Astria Therapeutics is dedicated to developing transformative therapies for individuals suffering from allergic and immunological conditions. The company's main focus is on its lead program, STAR-0215, which is a monoclonal antibody inhibitor targeting plasma kallikrein. This drug is currently in clinical development for the treatment of hereditary angioedema, a rare and potentially life-threatening genetic disorder characterized by recurrent episodes of severe swelling.

In addition to STAR-0215, Astria Therapeutics is also advancing another program, STAR-0310. This program involves a monoclonal antibody OX40 antagonist that is in the preclinical stage of development. STAR-0310 is being investigated for its potential to treat atopic dermatitis, a chronic inflammatory skin condition that affects a significant portion of the population.

The announcement of the upcoming presentation underscores Astria Therapeutics' commitment to advancing its clinical programs and sharing its latest research findings with the medical community. By presenting at the Eastern Allergy Conference, the company aims to provide valuable insights into the progress and potential of STAR-0215, contributing to the broader understanding and treatment of hereditary angioedema.

Astria Therapeutics continues to focus on its mission to bring innovative therapies to patients and families affected by allergic and immunological diseases. The company's efforts to develop and advance its clinical programs reflect its dedication to improving the lives of those impacted by these conditions.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!